臨床外科77巻2号

2022年02月発行

特集 ガイドラインには書いていない 大腸癌外科治療のCQ—妥当な治療と適応を見直そう

治癒切除可能直腸癌に対するtotal neoadjuvant therapy（TNT）の推奨レジメンと臨床成績

著者： 秋吉高志¹ 向井俊貴¹ 日吉幸晴¹ 長嵜寿矢¹ 山口智弘¹ 福長洋介¹

所属機関： ¹がん研有明病院大腸外科

ページ範囲：P.194 - P.198

【ポイント】
◆進行直腸癌に対するtotal neoadjuvant therapy（TNT）は，これまでの術前化学放射線療法＋術後補助化学療法に比べて遠隔再発の抑制が期待できる．
◆TNTにより，今後watch and waitアプローチの適応となる症例の増加が見込まれる．
◆再発低リスク直腸癌に対するTNTの適応については，今後の検討が必要である．

参考文献

1）Fujita S, Mizusawa J, Kanemitsu Y, et al：Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage Ⅱ/Ⅲ Lower Rectal Cancer（JCOG0212）：A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg 266：201-207, 2017

2）Bosset JF, Calais G, Mineur L, et al：Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer：long-term results of the EORTC 22921 randomised study. Lancet Oncol 15：184-190, 2014

3）Cercek A, Roxburgh CSD, Strombom P, et al：Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol 4：e180071, 2018

4）Bahadoer RR, Dijkstra EA, van Etten B, et al：Short-course radiotherapy followed by chemotherapy before total mesorectal excision（TME）versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer（RAPIDO）：a randomised, open-label, phase 3 trial. Lancet Oncol 22：29-42, 2021

5）Conroy T, Bosset JF, Etienne PL, et al：Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer（UNICANCER-PRODIGE 23）：a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22：702-715, 2021

6）Dahlbäck C, Korsbakke K, Alshibiby Bergman T, et al：Accuracy of magnetic resonance imaging staging of tumour and nodal stage in rectal cancer treated by primary surgery：a population-based study. Colorectal Dis 2021 Sep 7. doi：10.1111/codi.15905.〔Online ahead of print〕

7）Fernández-Martos C, Pericay C, Aparicio J, et al：Phase Ⅱ, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin（CAPOX）compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer：Grupo cancer de recto 3 study. J Clin Oncol 28：859-865, 2010

8）Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al：Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery：long-term results of the Spanish GCR-3 phase Ⅱ randomized trial†. Ann Oncol 26：1722-1728, 2015

9）Fernández-Martos C, Pericay C, Losa F, et al：Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma：The GEMCAD 1402 Randomized Clinical Trial. JAMA Oncol 5：1566-1573, 2019

10）Konishi T, Shinozaki E, Murofushi K, et al：Phase Ⅱ Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. Ann Surg Oncol 26：2507-2513, 2019

11）Zhou Y, Guo Z, Wu Z, et al：The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients：A systematic review and meta-analysis. Transl Oncol 14：100964, 2021

12）Garcia-Aguilar J, Chow OS, Smith DD, et al：Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer：a multicentre, phase 2 trial. Lancet Oncol 16：957-966, 2015

13）Bujko K, Wyrwicz L, Rutkowski A, et al：Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer：results of a randomized phase Ⅲ study. Ann Oncol 27：834-842, 2016

14）Ciseł B, Pietrzak L, Michalski W, et al：Long-course preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer：long-term results of the randomized Polish Ⅱ study. Ann Oncol 30：1298-1303, 2019

15）Garcia-Aguilar J, Patill S, Kim JK, et al：Preliminary results of the organ preservation of rectal adenocarcinoma（OPRA）trial. J Clin Oncol 38（15_suppl）：4008, 2020

16）Schrag D, Weiser M, Saltz L, et al：Challenges and solutions in the design and execution of the PROSPECT Phase Ⅱ/Ⅲ neoadjuvant rectal cancer trial（NCCTG N1048/Alliance）. Clin Trials 16：165-175, 2019

17）Brouquet A, Bachet JB, Huguet F, et al：NORAD01-GRECCAR16 multicenter phase Ⅲ non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer（intergroup FRENCH-GRECCAR- PRODIGE trial）. BMC Cancer 20：485, 2020